Landscape of vaccine access and health technology assessment role in decision-making process in ASEAN countries

References

• World Health Organization. WHO recommendations for routine immunization - summary tables 2019. [updated 26 April 2019; accessed 2020 Jan 09]. . https://www.who.int/immunization/policy/immunization_tables/en/.
   Google Scholar
• Griesenauer RH, Kinch MS. An overview of FDA-approved vaccines & their innovators. Expert Rev Vaccines. 2017;16(12):1253–66. doi:10.1080/14760584.2017.1383159.
   PubMed Web of Science ®Google Scholar
• Tantivess S, Chalkidou K, Tritasavit N, Teerawattananon Y. Health Technology Assessment capacity development in low- and middle-income countries: experiences from the international units of HITAP and NICE [version 1; peer review: 2 approved]. F1000Research. 2017;6:2119. doi:10.12688/f1000research.13180.1.
   PubMedGoogle Scholar
• Quang VT, Pham T. Health technology assessment in developing countries: a brief introduction for vietnamese health-care policymakers. Asian J Pharm. 2018;12:S1–S7.
   Web of Science ®Google Scholar
• Burchett HED, Mounier-Jack S, Griffiths UK, Mills AJ. National decision-making on adopting new vaccines: a systematic review. Health Policy Plan. 2011;27(suppl_2):ii62–ii76. doi:10.1093/heapol/czr049.
   PubMedGoogle Scholar
• The ASEAN Secretariat. Report of the ASEAN vaccine baseline survey (AVBS) 2017: - current situation and gap analysis. Jakarta: The Association of Southeast Asian Nations (ASEAN); 2017 August 2019.
   Google Scholar
• Gupta I, Guin P. Communicable diseases in the South-East Asia Region of the World Health Organization: towards a more effective response. Bull World Health Organ. 2010;88(3):199–205. doi:10.2471/BLT.09.065540.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO recommendations for routine immunization - summary tables 2019 [updated 2019 April 26] [accessed 2020 Jan 09]. https://www.who.int/immunization/policy/immunization_tables/en/.
   Google Scholar
• Centers of Disease Control and Prevention. List of vaccines used in United States 2018. [updated 2018 April 13] [accessed 2020 Jan 09]. https://www.cdc.gov/vaccines/vpd/vaccines-list.html.
   Google Scholar
• L Ag B, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S Human papillomavirus and related diseases in Brunei. Summary report. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre); 17 June 2019.
   Google Scholar
• Bruni LAG, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S Human papillomavirus and related diseases in Philippines. Summary report. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre); 17 June 2019.
   Google Scholar
• Bruni LAG, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S Human papillomavirus and related diseases in Thailand. Summary report. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre); 17 June 2019.
   Google Scholar
• Bruni LAG, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S Human papillomavirus and related diseases in Singapore. Summary report. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre); 17 June 2019.
   Google Scholar
• Bruni LAG, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S Human papillomavirus and related diseases in Malaysia. Summary report. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre); 17 June 2019.
   Google Scholar
• World Health Organization. Year of introduction of selected vaccines database 2019 [updated 2019 December 13] [cited 2020 Jan 10]. https://www.who.int/immunization/monitoring_surveillance/data/en/.
   Google Scholar
• Eng P, Lim LH, Loo CM, Low JA, Tan C, Tan EK, Wong SY, Setia S. Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in Singapore. Int J Gen Med. 2014;7:179–91. doi:10.2147/IJGM.S54963.
   PubMedGoogle Scholar
• Satzke C, Dunne EM, Choummanivong M, Ortika BD, Neal EFG, Pell CL, Nation ML, Fox KK, Nguyen CD, Gould KA, et al. Pneumococcal carriage in vaccine-eligible children and unvaccinated infants in Lao PDR two years following the introduction of the 13-valent pneumococcal conjugate vaccine. Vaccine. 2019;37(2):296–305. doi:10.1016/j.vaccine.2018.10.077.
   PubMed Web of Science ®Google Scholar
• Sundoro J Immunization programme in Indonesia: overview (focusing on Streptococcus pneumonia wholecell vaccine). 4th International Conference on Vaccines & Vaccination; Valencia Convention Centre, Spain, 2014. p. 126.
   Google Scholar
• Turner P, Turner C, Suy K, Soeng S, Ly S, Miliya T, Goldblatt D, Day NPJ. Pneumococcal infection among children before introduction of 13-valent pneumococcal conjugate vaccine, Cambodia. Emerg Infect Dis. 2015;21(11):2080–83. doi:10.3201/eid2111.150914.
   PubMed Web of Science ®Google Scholar
• Muangchana C Rota vaccine introduction in the Thai National program. 16th Annual Scientific Meeting of CEID; 11 June 2019; School of Public Health, Prince of Wales Hospital Shatin, New Territories (Hong Kong SAR), 2019. p. 1–56.
   Google Scholar
• Abou-Nader AJ, Sauer MA, Steele AD, Tate JE, Atherly D, Parashar UD, Santosham M, Nelson EAS. Global rotavirus vaccine introductions and coverage: 2006 – 2016. Hum Vaccin Immunother. 2018;14(9):2281–96. doi:10.1080/21645515.2018.1470725.
   PubMed Web of Science ®Google Scholar
• Doherty J. Effective capacity-building strategies for health technology assessment: a rapid review of international experience. South Africa: Discussion Document. School of Public Health, University of the Witwatersrand; 2015.
   Google Scholar
• MacDonald NE, Duclos P, Wichmann O, Henaff L, Harnden A, Alshammary A, Tijerino RA, Hall M, Sacarlal J, Singh RR, et al. Moving forward on strengthening and sustaining National immunization technical advisory groups (NITAGs) globally: recommendations from the 2nd global NITAG network meeting. Vaccine. 2017;35(50):6925–30. doi:10.1016/j.vaccine.2017.10.048.
   PubMed Web of Science ®Google Scholar
• Pediatric department Siriraj hospital. Immunisation schedule for newborn to 18-month child. 2017 [updated 2017] [cited 2020 Jan 19]. https://www.si.mahidol.ac.th/th/department/pediatrics/pdf/service/leftlet/InfectiousDiseases/vaccine_siriraj2560.pdf.
   Google Scholar
• Adjagba A, Henaff L, Duclos P. The NITAG resource centre (NRC): A one-stop shop towards a collaborative platform. Vaccine. 2015;33.
   PubMed Web of Science ®Google Scholar
• Edwards K, Decker M. Pertussis vaccine 5th. USA. p. 471–528.
   Google Scholar
• uex health insurance. How much do vaccines cost in Singapore? 2018 [updated 09 May 2018] [accessed 2020 Jan 19]. https://uexglobal.com/2018/05/09/costs-vaccinations-singapore/.
   Google Scholar
• Unicef. Vaccine price data: Unicef for every child; 2019 [updated 19 December 2019 [cited 2020 Jan 19. https://www.unicef.org/supply/index_57476.html.
   Google Scholar
• Skibinski DA, Baudner BC, Singh M, O’Hagan DT. Combination vaccines. J Glob Infect Dis. 2011;3(1):63–72. doi:10.4103/0974-777X.77298.
   PubMedGoogle Scholar
• World Health Organization. WHO vaccine-preventable diseases: monitoring system. 2019 global summary 2019 [updated 10 December 2019] [accessed 2020 Jan 09]. https://apps.who.int/immunization_monitoring/globalsummary/.
   Google Scholar
• Kusnin F Immunisation program in Malaysia. VACCINOLOGY 2017 – III INTERNATIONAL SYMPOSIUM FOR ASIA PACIFIC EXPERTS; Hanoi, Vietnam, 2017.
   Google Scholar
• Pediatric Infectious Disease Society of Thailand. Immunization recommendation schedule in Thai children 2019. In: media-20190620135123, editor. 2019.
   Google Scholar
• Gavi The Vaccine Alliance. Eligibility. 2019 [updated 2019] [accessed 2020 Jan 09]. https://www.gavi.org/types-support/sustainability/eligibility.
   Google Scholar
• Liverani M, Chheng K, Parkhurst J. The making of evidence-informed health policy in Cambodia: knowledge, institutions and processes. BMJ Global Health. 2018;3(3):e000652–e. doi:10.1136/bmjgh-2017-000652.
   PubMed Web of Science ®Google Scholar
• Rattanavipapong W, Kapoor R, Teerawattananon Y, Luttjeboer J, Botwright S, Archer RA, Giersing B, Hutubessy RCW. Comparing 3 approaches for making vaccine adoption decisions in Thailand. Int J Health Policy Manage. 2020. doi:10.15171/ijhpm.2020.01.
   PubMed Web of Science ®Google Scholar
• Bakri DDR, Sabirin J, Fuzi SAM, Rahman MA, Mohamad NF, Rashid RAM Health technology assessment manual. Malaysia: Medical Development Division, Ministry of Health; 2015 [cited 2020 Jan 09]. https://apps.who.int/medicinedocs/documents/s22255en/s22255en.pdf.
   Google Scholar
• Gavi The Vaccine Alliance. Transitioning out of Gavi support 2019 [updated 2019] [accessed 2020 Jan 09]. https://www.gavi.org/types-support/sustainability/transition.
   Google Scholar
• Wilder-Smith A, Flasche S, Smith PG. Vaccine-attributable severe dengue in the Philippines. Lancet. 2019;394(10215):2151–52. doi:10.1016/S0140-6736(19)32525-5.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2019. Global Vaccine Action Plan. Regional reports on progress towards GVAP-RVAP goals, Annex to the GVAP review and lessons-learned report.
   Google Scholar
• Ongpoy R. The National immunization committee (NIC), A Philippine NITAG (National Immunization Technical Advisory Group). J Asian Asso Schools Pharm. 2017;6:47–54.
   Google Scholar
• Tiong Wei Wei YK. Childhood immunization Health Mo, editor. Singapore. p. 121–33.
   Google Scholar
• World Health Organization. Regional office for South-East A. The establishment and operation of national immunization technical advisory groups in the WHO South-East Asia Region. New Delhi: World Health Organization. Regional Office for South-East Asia; 2016. p. 2016.
   Google Scholar
• Teerawattananon Y, Chaikledkaew U. Guidelines for health technology assessment in Thailand Second Edition. Thailand; 2014. accessed 2020 Jan 09. http://www.hitap.net/wp-content/uploads/2017/06/Thai-HTA-guideline-UPDATES-Jmed-with-Cover.pdf.
   Google Scholar
• Kingkaew P. A way forward for the evaluation of health technologies for infectious diseases. J Med Assoc Thai. 2014;97:S87–93.
   PubMedGoogle Scholar
• World Health Organization Regional Office for the Western Pacific. The Lao People’s Democratic Republic health system review. 2014 [accessed 2020 Jan 09]. http://iris.wpro.who.int/handle/10665.1/10448.
   Google Scholar
• Pilasant S, Kulpeng W, Werayingyong P, Tritasavit N, Yamabhai I, Teerawattananon Y, Wangmo S, Tantivess S. Maternal and child health voucher scheme in Myanmar: a review of early stage implementation. BMC Health Serv Res. 2016;16(1):600. doi:10.1186/s12913-016-1850-3.
   PubMedGoogle Scholar
• NITAG RESOURCE CENTER. NITAG STATUS worldwide. 2017 [updated December 2017 [accessed 2020 Jan 13]. http://www.nitag-resource.org/map.
   Google Scholar
• Duclos P, Ortynsky S, Abeysinghe N, Cakmak N, Janusz C, Jauregui B, Mihigo R, Mosina L, Sadr-Azodi S, Takashima Y, et al. Monitoring of progress in the establishment and strengthening of national immunization technical advisory groups. Vaccine. 2012;30.
   Web of Science ®Google Scholar
• Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86(5):408–16. doi:10.2471/BLT.07.048769.
   PubMed Web of Science ®Google Scholar
• Md Yasin R, Raudzah A, Ng AJ, Ng P, Zaidatul A, Asmah I, Murtaza M, Parasakthy N, Mohd Yasmin MY, Cheong YM, et al. Epidemiology of streptococcus pneumoniae infection in Malaysia. Epidemiol Infect. 1999;122:77–82. doi:10.1017/S0950268898001605.
   PubMed Web of Science ®Google Scholar
• Piralam B, Tomczyk SM, Rhodes JC, Thamthitiwat S, Gregory CJ, Olsen SJ, Praphasiri P, Sawatwong P, Naorat S, Chantra S, et al. Incidence of Pneumococcal Pneumonia among adults in Rural Thailand, 2006–2011: implications for Pneumococcal vaccine considerations. Am J Trop Med Hyg. 2015;93(6):1140–47. doi:10.4269/ajtmh.15-0429.
   PubMed Web of Science ®Google Scholar
• Goonewardene ST, Tang C, Tan LT-H, Chan K-G, Lingham P, Lee L-H, Goh B-H, Pusparajah P. Safety and Efficacy of Pneumococcal vaccination in pediatric nephrotic syndrome. Front Pediatr. 2019;7:339. doi:10.3389/fped.2019.00339.
   PubMed Web of Science ®Google Scholar
• Turner P, Leab P, Ly S, Sao S, Miliya T, Heffelfinger JD, Batmunkh N, Lessa FC, Walldorf JA, Hyde TB, et al. Impact of 13-valent pneumococcal conjugate vaccine on colonization and invasive disease in cambodian children. Clin Infect Dis. 2019.
   Web of Science ®Google Scholar
• Wongsawat J, Chokephaibulkit K. Implication of pneumococcal conjugate vaccines to public health: thailand perspective. J Med Assoc Thai. 2010;93:S53–60.
   PubMedGoogle Scholar
• Dilokthornsakul P, Kengkla K, Saokaew S, Permsuwan U, Techasaensiri C, Chotpitayasunondh T, Chaiyakunapruk N. An updated cost-effectiveness analysis of pneumococcal conjugate vaccine among children in Thailand. Vaccine. 2019;37(32):4551–60. doi:10.1016/j.vaccine.2019.06.015.
   PubMed Web of Science ®Google Scholar
• Tyo KR, Rosen MM, Zeng W, Yap M, Pwee KH, Ang LW, Shepard DS. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine. 2011;29(38):6686–94. doi:10.1016/j.vaccine.2011.06.091.
   PubMed Web of Science ®Google Scholar
• Wu DB-C, Roberts C, Lee VWY, Hong L-W, Tan KK, Mak V, Lee KKC. Cost-effectiveness analysis of infant universal routine pneumococcal vaccination in Malaysia and Hong Kong. Hum Vaccin Immunother. 2016;12(2):403–16. doi:10.1080/21645515.2015.1067351.
   PubMed Web of Science ®Google Scholar
• Crawford SE, Ramani S, Tate JE, Parashar UD, Svensson L, Hagbom M, Franco MA, Greenberg HB, O’Ryan M, Kang G, et al. Rotavirus infection. Nat Rev Dis Primers. 2017;3(1):17083. doi:10.1038/nrdp.2017.83.
   PubMed Web of Science ®Google Scholar
• Kawai K, O’Brien MA, Goveia MG, Mast TC, El Khoury AC. Burden of rotavirus gastroenteritis and distribution of rotavirus strains in Asia: A systematic review. Vaccine. 2012;30(7):1244–54. doi:10.1016/j.vaccine.2011.12.092.
   PubMed Web of Science ®Google Scholar
• Clark A, van Zandvoort K, Flasche S, Sanderson C, Bines J, Tate J, Parashar U, Jit M. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. Lancet Infect Dis. 2019;19(7):717–27. doi:10.1016/S1473-3099(19)30126-4.
   PubMed Web of Science ®Google Scholar
• Phua KB, Lim FS, Lau YL, Nelson EAS, Huang LM, Quak SH, Lee BW, Doorn LJV, Teoh YL, Tang H, et al. Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population. Vaccine. 2012;30(30):4552–57. doi:10.1016/j.vaccine.2012.03.030.
   PubMed Web of Science ®Google Scholar
• Tharmaphornpilas P, Jiamsiri S, Boonchaiya S, Rochanathimoke O, Thinyounyong W, Tuntiwitayapun S, Guntapong R, Riewpaiboon A, Rasdjarmrearnsook A-O, Glass RI, et al. Evaluating the first introduction of rotavirus vaccine in Thailand: moving from evidence to policy. Vaccine. 2017;35(5):796–801. doi:10.1016/j.vaccine.2016.12.043.
   PubMed Web of Science ®Google Scholar
• Phua KB, Lim FS, Lau YL, Nelson EAS, Huang LM, Quak SH, Lee BW, Teoh YL, Tang H, Boudville I, et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine. 2009;27(43):5936–41. doi:10.1016/j.vaccine.2009.07.098.
   PubMed Web of Science ®Google Scholar
• Atherly D, Dreibelbis R, Parashar UD, Levin C, Wecker J, Rheingans RD. Rotavirus vaccination: cost-effectiveness and impact on child mortality in developing countries. J Infect Dis. 2009;200(Suppl 1):S28–38. doi:10.1086/605033.
   PubMed Web of Science ®Google Scholar
• Chotivitayatarakorn P, Chotivitayatarakorn P, Poovorawan Y. Cost-effectiveness of rotavirus vaccination part of the National Immunization Program for Thai children. Southeast Asian J Trop Med Public Health. 2010;41:114–25.
   PubMed Web of Science ®Google Scholar
• Braaten KP, Laufer MR. Human papillomavirus (HPV), HPV-related disease, and the HPV vaccine. Rev Obstet Gynecol. 2008;1:2–10.
   PubMedGoogle Scholar
• World Health Organization. Human papillomavirus (HPV) and cervical cancer. 2019 [updated 24 January 2019] [accessed 2020 Jan 09]. https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer.
   Google Scholar
• World Health Organization. Human papillomavirus vaccines: WHO position paper, May 20172017 12 MAY 2017 [accessed 2020 Jan 18]; 92:[241–68 pp.]. https://apps.who.int/iris/bitstream/handle/10665/255353/WER9219.pdf;jsessionid=7EEB41D6E39E3E04DBED47589DEE2C6A?sequence=1.
   Google Scholar
• Kosen S, Andrijono A, Ocviyanti D, Indriatmi W. The cost-effectiveness of quadrivalent human papillomavirus vaccination in Indonesia. Asian Pac J Cancer Prev. 2017;18(7):2011–17. doi:10.22034/APJCP.2017.18.7.2011.
   PubMedGoogle Scholar
• Munoz N, Manalastas R Jr., Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949–57. doi:10.1016/S0140-6736(09)60691-7.
   PubMed Web of Science ®Google Scholar
• Satari HI, Sundoro J, Andrijono A, Hadinegoro SR, Syafriyal S, Tandy G, Karolina S. Post marketing surveillance study of 2nd dose quadrivalent human papilloma virus vaccine in elementary school children in jakarta, indonesia: safety result and implementation of school-based HPV immunization program. Asian Pac J Cancer Prev. 2019;20(3):869–75. doi:10.31557/APJCP.2019.20.3.869.
   PubMedGoogle Scholar
• Arbyn M, Xu L. Efficacy and safety of prophylactic HPV vaccines. A Cochrane review of randomized trials. Expert Rev Vaccines. 2018;17(12):1085–91. doi:10.1080/14760584.2018.1548282.
   PubMed Web of Science ®Google Scholar
• Chanthavilay P, Reinharz D, Mayxay M, Phongsavan K, Marsden DE, Moore L, White LJ. The economic evaluation of human papillomavirus vaccination strategies against cervical cancer in women in Lao PDR: a mathematical modelling approach. BMC Health Serv Res. 2016;16(1):418. doi:10.1186/s12913-016-1662-5.
   PubMedGoogle Scholar
• Termrungruanglert W, Havanond P, Khemapech N, Lertmaharit S, Pongpanich S, Khorprasert C, Taneepanichskul S. Cost and Effectiveness Evaluation of Prophylactic HPV Vaccine in Developing Countries. Value Health. 2012;15(1,Supplement):S29–S34. doi:10.1016/j.jval.2011.11.007.
   PubMed Web of Science ®Google Scholar
• Tay SK, Lee B-W, Sohn WY, Lee IH, Mathur G, Sanicas M, Van Kriekinge G. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore. Singapore Med J. 2018;59(7):370–82. doi:10.11622/smedj.2017085.
   PubMed Web of Science ®Google Scholar
• Ezat WP, Aljunid S. Cost-effectiveness of HPV vaccination in the prevention of cervical cancer in Malaysia. Asian Pacific J Cancer Prev. 2010;11:79–90.
   PubMedGoogle Scholar
• Van Minh H, My NTT, Jit M. Cervical cancer treatment costs and cost-effectiveness analysis of human papillomavirus vaccination in Vietnam: a PRIME modeling study. BMC Health Serv Res. 2017;17(1):353. doi:10.1186/s12913-017-2297-x.
   PubMedGoogle Scholar
• World Health Organization Western Pacific Region. Update on the Dengue situation in the Western Pacific Region. 2019 [updated 19 December 2019] cited 2020 Jan 09]. https://www.who.int/docs/default-source/wpro—documents/emergency/surveillance/dengue/dengue-20191219.pdf?sfvrsn=b42cfbd0_22.
   Google Scholar
• Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet. 2014;384(9951):1358–65. doi:10.1016/S0140-6736(14)61060-6.
   PubMed Web of Science ®Google Scholar
• Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012;380(9853):1559–67. doi:10.1016/S0140-6736(12)61428-7.
   PubMed Web of Science ®Google Scholar
• Tran H. Safety and immunogenicity of recombinant, live attenuated tetravalent dengue vaccine (CYD- TDV) in healthy vietnamese adults and children. J Vaccines Vaccin. 2012;03.
   Google Scholar
• Sin Leo Y, Wilder-Smith A, Archuleta S, Shek LP, Chong CY, Nam Leong H, Yong Low C, Oh MLH, Bouckenooghe A, Wartel TA, et al. Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years. Hum Vaccin Immunother. 2012;8(9):1259–71. doi:10.4161/hv.21224.
   PubMed Web of Science ®Google Scholar
• Shafie AA, Yeo HY, Coudeville L, Steinberg L, Gill BS, Jahis R, HSS A-S. The potential cost effectiveness of different dengue vaccination programmes in Malaysia: a value-based pricing assessment using dynamic transmission mathematical modelling. PharmacoEconomics. 2017;35(5):575–89. doi:10.1007/s40273-017-0487-3.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Revised SAGE recommendation on use of dengue vaccine. 2018 [updated 19 April 2018] [accessed 2020 Apr 18]. https://www.who.int/immunization/diseases/dengue/revised_SAGE_recommendations_dengue_vaccines_apr2018/en/.
   Google Scholar
• Carrasco LR, Lee LK, Lee VJ, Ooi EE, Shepard DS, Thein TL, Gan V, Cook AR, Lye D, Ng LC, et al. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore. PLoS Negl Trop Dis. 2011;5(12):e1426–e. doi:10.1371/journal.pntd.0001426.
   PubMed Web of Science ®Google Scholar
• Zeng W, Halasa-Rappel YA, Baurin N, Coudeville L, Shepard DS. Cost-effectiveness of dengue vaccination in ten endemic countries. Vaccine. 2018;36(3):413–20. doi:10.1016/j.vaccine.2017.11.064.
   PubMed Web of Science ®Google Scholar
• Padmawati RS, Heywood A, Sitaresmi MN, Atthobari J, MacIntyre CR, Soenarto Y, Seale H. Religious and community leaders’ acceptance of rotavirus vaccine introduction in Yogyakarta, Indonesia: a qualitative study. BMC Public Health. 2019;19(1):368. doi:10.1186/s12889-019-6706-4.
   PubMedGoogle Scholar
• World Health Organization. Safety of dengue vaccine in the Philippines: WHO weekly epidemiological record. 2018 [updated 20 July 2018] [cited 2020 Apr 08]. https://www.who.int/vaccine_safety/committee/topics/dengue/June_2018/en/.
   Google Scholar
• Botwright S, Holroyd T, Nanda S, Bloem P, Griffiths UK, Sidibe A, Hutubessy RCW. Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects. PLoS One. 2017;12(10):e0182663–e. doi:10.1371/journal.pone.0182663.
   PubMed Web of Science ®Google Scholar
• Setiawan D, Oktora MP, Hutubessy R, Riewpaiboon A, Postma MJ. The health-economic studies of HPV vaccination in Southeast Asian countries: a systematic review. Expert Rev Vaccines. 2017;16(9):933–43. doi:10.1080/14760584.2017.1357472.
   PubMed Web of Science ®Google Scholar